Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title			Study Status	Performance Against Target
	·			Closed - In Follow	
09/H0406/110	CCRN 127 (CHF)	6	16/10/2012	Up	Target Not Met
				Closed - Follow	
11/SW/0054	Infant Peptide Feed Study	3	31/10/2012	Up Complete	Target Met
				Closed follow up	
08/H0504/179	MCRN035 (BUP1501)	5	22/11/2012	complete	Target Not Met
				Closed - Follow	
11/SC/0313	(MCRN 144) 115345 (FLU D-QIV-004 PRI)	90	30/11/2012	Up Complete	Target Met
	MYELOMA FOCUS (PX-171-01): A Randomised, open-label, phase 3				
	study of Carfilzomib vs best supportive care in subjects with relapsed			Closed - Follow	
11/SC/0479	and refractory multiple myeloma.	5	30/11/2012	Up Complete	Target Not Met
				Closed - Follow	
12/SW/0237	116023 (FLU D-QIV-009 EXT 004)	5	30/11/2012	Up Complete	Target Met
				Closed - In Follow	
08/H0206/24	Narrow AstraTech Dental Implants YA-NAR-0001	10	07/12/2012	Up	Target Met
				Closed - Follow	
10/H1008/51	NCRN124 - Elacytarabine as 2nd line salvage therapy in AML	5	30/12/2012	Up Complete	Target Met
				Closed - Follow	
09/H0101/60	Flash ultrasound detection of cancer and vascular disease	30	31/12/2012	Up Complete	Target Not Met
				Closed - Follow	
11/SW/0141	System One Evaluation	5	31/12/2012	Up Complete	Target Not Met
				Closed - Follow	
09/H0408/58	Treatment of influenza with osletamivir in transplant patients	2	31/12/2012	Up Complete	Target Not Met
				Closed - In Follow	
12/NE/0004	PBC OCA International Study of Efficacy (POISE 747-301)	5	31/12/2012		Target Not Met
	Study of GS7977 with Ribavirin in patients with HCV infection (GS-US-			Closed - In Follow	
12/NE/0266	334-0133 - Valence)	5	31/12/2012	•	Target Met
	SWAP 2: A Pharmacodynamic Evaluation of Switching from Ticagrelor			Closed - Follow	
12/SC/0318	to Prasugrel (CS747S-B-U4003)	5	11/01/2013	Up Complete	Target Not Met

Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title	Target	End Date	Study Status	Performance Against Target
	H6D-MC-LVIG: Study of Tadalafil in Children with Pulmonary Arterial			Closed - Follow	
12/LO/0050	Hypertension (MCRN159)	2	24/01/2013	Up Complete	Target Not Met
11/LO/1728	MCRN128 (CL2-16257-090)	2	31/01/2013	Withdrawn	Target Not Met
				Closed - In Follow	
12/LO/0372	ALLERGAN DME 206207-024	4	01/02/2013	Up	Target Not Met
				Closed - Follow	
10/H0606/78	CCRN 378 (Crohn's)	6	28/02/2013	Up Complete	Target Not Met
	INTERNATIONAL (NCRN 336): BITE - ALL MT103-211: Phase II Trial with			Closed - In Follow	
11/LO/1733	Blinatumomab in relapsed/refractory B-precursor ALL	2	28/02/2013	•	Target Met
	(CCRN 311)ATOMIC-HF - Phase 2 Study with AMG 423 in Acute Heart			Closed - In Follow	
11/LO/0886	Failure	4	30/03/2013		Target Not Met
				Closed - Follow	
11/H0606/6	Crohn's Disease Maintenance Trial - CCX114157 (CCRN 381)	3	31/03/2013	Up Complete	Target Not Met
				Closed - In Follow	
12/SC/0024	CRYSTAL CRFB002E2401	5	31/03/2013	•	Target Met
				Closed - In Follow	
12/SC/0469	EFC12492: Odyssey FH I	5	08/04/2013		Target Met
				Closed - In Follow	
12/EE/0499	MK-5172 with peg-IFN and RBV in HCV Infected Subjects	5	09/05/2013		Target Not Met
				Closed - In Follow	
12/SC/0025	BRIGHTER (CRFB002E2402)	5	31/05/2013		Target Met
				Closed - In Follow	
11/LO/0743	PARACHUTE III	4	01/06/2013		Target Not Met
				Closed - In Follow	
11/LO/1408	ABSORB II	10	30/06/2013	•	Target Met
12/12/22	GO27819 Phase II Study of MetMAb in Patients with Recurrent		00/06/05:5	Closed - In Follow	
12/LO/0582	Glioblastoma	12	30/06/2013	Up	Target Not Met

Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title			Study Status	Performance Against Target
	·			Closed - In Follow	
12/SC/0540	BI 207127 in Treatment-Naïve Patients with HCV	5	30/06/2013	Up	Target Not Met
				Closed follow up	
H/0604/01	CCRN 427 (Crohn's extension)	3	05/07/2013	complete	Target Not Met
				Closed follow up	
10/H1002/1	MCRN063 (TAK-491_109)	3	31/07/2013	complete	Target Not Met
10/H1008/83	MCRN090 (20090005)	1	31/07/2013	Suspended	Target Not Met
				Closed - In Follow	
11/SC/0177	CCRN 530 (Hep C)	1	31/08/2013	Up	Target Met
	NCRN322 TERRAIN: MDV3100 (ASP9785) vs. Bicalutamide Metastatic			Closed - In Follow	
11/LO/0608	Prostate Cancer	5	31/08/2013	Up	Target Met
				Closed - In Follow	
11/SC/0326	UNITI 1	5	31/08/2013	Up	Target Not Met
	V72P12E2 - A new vaccine against meningitis groupB: A second follow-			Closed follow up	
12/SC/0384	on	52	31/08/2013	complete	Target Met
(0	0	00/01/1900	#N/A	#N/A
	NCRN469 COMET 1: Cabozantinib vs Prednisone in mCRPC after prior				
12/LO/1156	therapy	5	16/09/2013	Open	Still open to Recruitment
	NCRN069 ORCHARRD - Ofatumumab vs Rituximab followed by ASCT in				
09/H0406/106	DLBCL	5	31/10/2013	Open	Still open to Recruitment
11/LO/1023	CCRN 492 (Branch retinal vein occlusion)	10	31/10/2013	Open	Still open to Recruitment
	NCRN325 HOPE: E7080 +/- Everolimus in mRCC following one prior				
11/L0/0619	VEGF-targeted treatment	4	31/10/2013	Open	Still open to Recruitment
				Closed - In Follow	
12/LO/0250	MATISSE STUDY	6	31/10/2013	Up	Target Met
11/LO/1810	DEFLECT I Trial	6	31/10/2013	Open	Still open to Recruitment
	CCRN 2010 - Baxter 261201: PEGylated Recombinant Factor VIII in				
13/EM/0084	Severe Hemophilia A	2	31/10/2013	Open	Still open to Recruitment

Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title	Target	End Date	Study Status	Performance Against Target
	A randomized control trial of non-invasive ventilation during an				
	exercise programme following acute acidotic exacerbation of COPD in				
	hospital and follow-up use at home: feasibility of using the Trilogy				
12/SW/0228	Ventilator.	37	30/11/2013	Open	Still open to Recruitment
	A3921095: 007: Oral CP690,550 as an Induction Therapy for Ulcerative				
12/LO/0080	Colitis	5	30/11/2013	In set up	Still open to Recruitment
	A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for				
12/LO/0081	Ulcerative Colitis	3	30/11/2013	In set up	Still open to Recruitment
	A3291139: 009: Open- label oral CP690,550 for Treatment of				
12/LO/0082	Ulcerative Colitis	5	30/11/2013	In set up	Still open to Recruitment
10/H0808/138	CCRN 499 (CV)	10	30/12/2013	Open	Still open to Recruitment
10/H1308/84	NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	1	31/12/2013	Open	Still open to Recruitment
	OSI-906: Phase 2 Study of OSI906 and Erlotinib in Patients with			Closed - In Follow	
10/H0406/90	Advanced NSCLC and Erlotinib in Patients with Advanced NSCLC	3	31/12/2013		Target Not Met
10/H0400/90 10/H0711/66	BLAST NCRN170	2		•	Still open to Recruitment
10/10/11/00	DLASI NCKN170		31/12/2013	Closed - In Follow	Still open to Recruitment
11/VM/0279	NECTAR-HF Research Study	6	31/12/2013		Target Not Met
11/VN/0279 11/LO/1226	CCRN 592 (Uveitis)	10		•	Still open to Recruitment
11/10/1226	CANTOS: CACZ885M2301 Canakinumab in postMI patients with raised	10	31/12/2013	Ореп	Still open to Recruitment
12/EM/0018	hsCRP	8	31/12/2013	Withdrawn	Target Not Met
12/LO/1358	NCRN532 (TAS 102)	7			Still open to Recruitment
13/SW/0072	CCRN 2149 - FTY720D2205	3			Still open to Recruitment
13/311/00/2	COM 2113 11172052203		31/12/2013	Closed - In Follow	Still open to Recruitment
13/SC/0171	VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis	3	31/12/2013		Target Not Met
12/WA/1064	ZEST	4		•	Still open to Recruitment
· ·	Extension study of GS-7977 in patients with HCV infection (GS-US-334-				,
12/EE/0400	0109)	5	27/01/2014	In set up	Still open to Recruitment
12/SW/0084	LFG316 MFC	5		The state of the s	Still open to Recruitment

Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title	Target	End Date	Study Status	Performance Against Target
12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4	28/02/2014	Open	Still open to Recruitment
13/SC/0213	ACT IV Study - Protocol CDX110-04	6	03/03/2014	Open	Still open to Recruitment
	CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven				
13/EM/0254	Macular Oedema (CRFB002G2302)	3	28/03/2014	In set up	Still open to Recruitment
13/NW/0464	Pharmacokinetic and Pharmacodynamic Trial of IDN6556	4	30/03/2014	Open	Still open to Recruitment
	A Phase 2 MultiCenter, Historically Controlled Study of Dasatinib				
	Added to Standard Chemotherapy in Pediatric Patients with Newly				
	Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic				
11/WA/0363	Leukemia (Ph+ ALL)	1	31/03/2014	Open	Still open to Recruitment
11/SC/0327	CCRN 601 (Crohn's Disease)	5	30/06/2014	Open	Still open to Recruitment
12/SC/0502	Pfizer B1181003 Clinical Study of RN6G (PF-04382923)	3	30/06/2014	Withdrawn	Target Not Met
12/NW/0585	Trastuzumab Emtansine (TDM1) (GATSBY)	2	31/07/2014	Open	Still open to Recruitment
13/YH/022	MCI-196-E16	2	31/07/2014	Open	Still open to Recruitment
	NCRN398 IMAGE: Observational Study in Patients with Unresectable				
12/WA/0058	or Metastatic Melanoma	10	31/07/2014	Open	Still open to Recruitment
10/H0406/46	ABBOTT 880 CCRN 282 (Inactive uveitis)	4	17/08/2014	Open	Still open to Recruitment
10/H0406/45	ABBOTT 877 CCRN 281 (Active uveitis)	4	16/09/2014	Open	Still open to Recruitment
10/H0406/47	ABBOTT 327 CCRN 283 (LT uveitis)	8	30/09/2014	Open	Still open to Recruitment
12/SC/0309	B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia	1	28/10/2014	Open	Still open to Recruitment
13/YH/0021	MCI-196-E15 Extension Study Evaluating Colestilan	2	31/12/2014	Open	Still open to Recruitment
12/NW/0367	MCRN177 (BEL114055)	1	31/12/2014	Open	Still open to Recruitment
12/LO/1876	COBRIM - GO28141	5	31/12/2014	Open	Still open to Recruitment
12/NW/0641	NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	8	31/12/2014	Open	Still open to Recruitment
13/EE/0263	MASTER II	20	31/12/2014	Open	Still open to Recruitment
13/LO/0150	RESORCE: The regorafenib in patients with hepatocellular carcinoma	2	01/02/2015	Open	Still open to Recruitment
	Intravenous zanamivir versus oral oseltamivir in hospitalised influenza				
10/H1003/120	(NAI114373 - ZORO)	2	27/02/2015	Open	Still open to Recruitment
11/NW/0298	Gallium	14	31/03/2015	Open	Still open to Recruitment

Research Ethics		Recruit			
Committee		ment	Recruitment		
Reference	Study Title	Target	End Date	Study Status	Performance Against Target
12/LO/1090	YO28322	4	01/06/2015	Open	Still open to Recruitment
	PERUSE (MO28047): Global safety study with pertuzumab in Her2+			Closed - Follow	
12/LO/O482	advanced BC	5	31/03/2016	Up Complete	Target Not Met
	OCTAVE, Ranibizumab in neovascular age-related macular				
13/LO/0520	degeneration(CRFB002A2405)	4	16/04/2016	Open	Still open to Recruitment
	Jigsaw WA28117 [POLYARTICULAR-COURSE JUVENILE IDIOPATHIC				
13/NW/0320	ARTHRITIS]	2	30/04/2016	Open	Still open to Recruitment
13/WA/0101	CCRN 2088 (Pneumonia)	6	30/04/2016	In set up	Still open to Recruitment
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	2	17/05/2016	In set up	Still open to Recruitment
	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with				
13/EM/0012	malignant melanoma	1	30/06/2016	Open	Still open to Recruitment
09/H0802/125	MCRN062 (NAI113678)	1	27/01/2017	Open	Still open to Recruitment
11/LO/0923	NCRN259 HERBY - Bevacizumab in paediatric high grade glioma	3	22/08/2017	Open	Still open to Recruitment
11/SC/0329	CCRN 602 (Crohn's disease)	5	31/10/2017	Open	Still open to Recruitment
	BERNIE: Bevacizumab and standard chemotherapy in childhood soft-				
09/H0718/18	tissue sarcoma	4	01/02/2018	Open	Still open to Recruitment